Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C

Digestive Diseases and Sciences

Volumn 54, Issue 11, 2009, Pages 2530-2537

  Tamura, Yasushi ^a,b   Yamagiwa, Satoshi ^a,b   Aoki, Yohei ^a,b   Kurita, So ^a,b   Suda, Takeshi ^a,b   Ohkoshi, Shogo ^a,b   Nomoto, Minoru ^a,b   Aoyagi, Yutaka ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Niigata Liver Disease Study Group   (Japan)

Author keywords

Alpha fetoprotein; Chronic hepatitis C; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; CONSENSUS INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350221879     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0642-y     Document Type: Article

References (37)

1. J Bruix JM Barrera X Calvet G Ercilla J Costa JM Sanchez-Tapias M Ventura M Vall M Bruguera C Bru 1989 Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis Lancet 334 1004 1046 10.1016/S0140-6736(89)91015-5 10.1016/S0140-6736(89)91015-5
2. M Colombo G Kuo QL Choo MF Donato E Del Ninno MA Tommasini N Dioguardi M Houghton 1989 Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma Lancet 334 1006 1008 10.1016/S0140-6736(89)91016-7 10.1016/S0140-6736(89)91016-7
3. F Hasan LJ Jeffers M De Medina KR Reddy T Parker ER Schiff M Houghton QL Choo G Kuo 1990 Hepatitis C-associated hepatocellular carcinoma Hepatology 12 589 591 10.1002/hep.1840120323 10.1002/hep.1840120323 2169456
4. K Ikeda S Saitoh I Koida Y Arase A Tsubota K Chayama H Kumada M Kawanishi 1993 A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis Hepatology 18 47 53 10.1002/hep.1840180109 7686879
5. H Tsukuma T Hiyama S Tanaka M Nakao T Yabuuchi T Kitamura K Nakanishi I Fujimoto A Inoue H Yamazaki T Kawashima 1993 Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1797 1801 10.1056/NEJM199306243282501 10.1056/NEJM199306243282501 7684822 (Pubitemid 23174709)
6. GL Davis LA Balart ER Schiff K Lindsay HC Bodenheimer Jr RP Perrillo W Carey IM Jacobson J Payne JL Dienstag 1989 Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group N Engl J Med 321 1501 1506 2509916
7. AM Di Bisceglie P Martin C Kassianides M Lisker-Melman L Murray J Waggoner Z Goodman SM Banks JH Hoofnagle 1989 Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1506 1510 2509917
8. X Causse H Godinot M Chevallier P Chossegros F Zoulim D Ouzan JP Heyraud T Fontanges J Albrecht C Meschievitz 1991 Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 101 497 502 1906028
9. K Chayama S Saitoh Y Arase K Ikeda T Matsumoto Y Sakai M Kobayashi M Unakami T Morinaga H Kumada 1991 Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C Hepatology 13 1040 1043 10.1002/hep.1840130606 1711001
10. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima S Shiomi S Seki K Kobayashi S Otani 1995 Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051 1055 10.1016/S0140-6736(95)91739-X 10.1016/S0140-6736(95)91739-X 7564784
11. K Ikeda S Saitoh Y Arase K Chayama Y Suzuki M Kobayashi A Tsubota I Nakamura N Murashima H Kumada M Kawanishi 1999 Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1124 1130 10.1002/hep.510290439 10.1002/hep.510290439 10094956
12. A Makiyama Y Itoh A Kasahara Y Imai S Kawata K Yoshioka H Tsubouchi K Kiyosawa S Kakumu K Okita N Hayashi T Okanoue 2004 Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy Cancer 101 1616 1622 10.1002/cncr.20537 10.1002/cncr.20537 15378504 (Pubitemid 39318909)
13. M Ikeda S Fujiyama M Tanaka M Sata T Ide H Yatsuhashi H Watanabe 2005 Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon J Gastroenterol 40 148 156 10.1007/s00535-004-1519-2 10.1007/s00535-004-1519-2 15770398 (Pubitemid 40425202)
14. GI Abelev 1968 Production of embryonal serum alpha-globulin by hepatoma: review of experimental and clinical data Cancer Res 28 1344 1350 4174340
15. GI Conor YS Tatarinov GI Abelev J Uriel 1970 A collaborative study for the evaluation of a serologic test for primary liver cancer Cancer 25 1091 1098 10.1002/1097-0142(197005)25:5<1091::AID-CNCR2820250514>3.0.CO;2-P 10.1002/1097-0142(197005)25:5<1091::AID-CNCR2820250514>3.0.CO;2-P
16. N Bayati AL Silverman SC Gordon 1998 Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C Am J Gastroenterol 93 2452 2456 10.1111/j.1572-0241.1998.00703.x 10.1111/j.1572-0241.1998.00703.x 9860408 (Pubitemid 29018554)
17. NS Goldstein DE Blue R Hankin S Hunter N Bayati AL Silverman SC Gordon 1999 Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores Am J Clin Pathol 111 811 816 10361518
18. CW Chu SJ Hwang JC Luo CR Lai SH Tsay CP Li JC Wu FY Chang SD Lee 2001 Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C J Clin Gastroenterol 32 240 244 10.1097/00004836-200103000-00014 10.1097/00004836- 200103000-00014 11246354 (Pubitemid 32174119)
19. KQ Hu NL Kyulo N Lim B Elhazin DJ Hillebrand T Bock 2004 Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma Am J Gastroenterol 99 860 865 10.1111/j.1572-0241.2004.04152.x 10.1111/j.1572-0241.2004.04152.x 15128351 (Pubitemid 39090214)
20. AM Di Bisceglie RK Sterling RT Chung JE Everhart JL Dienstag HL Bonkovsky EC Wright GT Everson KL Lindsay AS Lok WM Lee TR Morgan MG Ghany DR Gretch 2005 HALT-C Trial group: serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial J Hepatol 43 434 441 10.1016/j.jhep.2005.03.019 10.1016/j.jhep.2005.03.019 16136646 (Pubitemid 41111424)
21. S Murashima M Tanaka M Haramaki S Yutani Y Nakashima K Harada T Ide R Kumashiro M Sata 2006 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP Dig Dis Sci 51 808 812 10.1007/s10620-006-3211-2 10.1007/s10620-006-3211-2 16615008
22. TM Chen PT Huang MH Tsai LF Lin CC Liu KS Ho CP Siauw PL Chao JN Tung 2007 Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy J Gastroenterol Hepatol 22 669 675 17444854
23. H Nomura Y Kashiwagi R Hirano H Tanimoto N Tsutsui M Higashi H Ishibashi 2007 Efficacy of low-dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study Hepatol Res 37 490 497 10.1111/j.1872-034X.2007.00073.x 10.1111/j.1872-034X.2007.00073.x 17539990 (Pubitemid 46864243)
24. Y Arase F Suzuki Y Suzuki N Akuta M Kobayashi Y Kawamura H Yatsuji H Sezaki T Hosaka K Ikeda H Kumada 2008 Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease J Med Virol 80 1302 1307 10.1002/jmv.21195 10.1002/jmv.21195 18461628 (Pubitemid 351706012)
25. F Ichida T Tsuji M Omata T Ichida K Inoue T Kamimura G Yamada K Hino O Yokosuka H Suzuki 1996 New Inuyama Classification; new criteria for histological assessment of chronic hepatitis Int Hepatol Commun 6 112 119 10.1016/S0928-4346(96)00325-8 10.1016/S0928-4346(96)00325-8 (Pubitemid 27059904)
26. G Fattovich G Giustina F Degos F Tremolada G Diodati P Almasio F Nevens A Solinas D Mura JT Brouwer H Thomas C Njapoum C Casarin P Bonetti P Fuschi J Basho A Tocco A Bhalla R Galassini F Noventa SW Schalm G Realdi 1997 Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 463 472 10.1053/gast.1997.v112.pm9024300 10.1053/gast.1997.v112.pm9024300 9024300 (Pubitemid 27078833)
27. Y Sato K Nakata Y Kato M Shima N Ishii T Koji K Taketa Y Endo S Nagataki 1993 Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein N Engl J Med 328 1802 1806 10.1056/NEJM199306243282502 10.1056/NEJM199306243282502 7684823 (Pubitemid 23174710)
28. Y Niwa M Matsumura Y Shiratori M Imamura N Kato S Shiina T Okudaira Y Ikeda T Inoue M Omata 1996 Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma Hepatology 23 1384 1392 8675155
29. A Panduro F Shalaby FR Weiner L Biempica MA Zern DA Shafritz 1986 Transcriptional switch from albumin to alpha-fetoprotein and changes in transcription of other genes during carbon tetrachloride induced liver regeneration Biochemistry 25 1414 1420 10.1021/bi00354a034 10.1021/bi00354a034 2421766
30. XW Wang B Xu 1998 Stimulation of tumor-cell growth by alpha-fetoprotein Int J Cancer 75 596 599 10.1002/(SICI)1097-0215(19980209)75:4<596::AID- IJC17>3.0.CO;2-7 10.1002/(SICI)1097-0215(19980209)75:4<596::AID- IJC17>3.0.CO;2-7 9466662 (Pubitemid 28094107)
31. XW Wang H Xie 1999 Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro Life Sci 64 17 23 10.1016/S0024-3205(98)00529-3 10.1016/S0024-3205(98)00529-3 10027738 (Pubitemid 29012745)
32. MS Li PF Li Q Chen GG Du G Li 2004 Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells World J Gastroenterol 10 819 824 15040024
33. MS Li QL Ma Q Chen XH Liu PF Li GG Du G Li 2005 Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells World J Gastroenterol 11 2564 2569 15849812
34. CL Chen HI Yang WS Yang CJ Liu PJ Chen SL You LY Wang CA Sun SN Lu DS Chen CJ Chen 2008 Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan Gastroenterology 135 111 121 10.1053/j.gastro.2008.03.073 10.1053/j.gastro.2008.03.073 18505690 (Pubitemid 351899021)
35. MM Hassan LY Hwang CJ Hatten M Swaim D Li JL Abbruzzese P Beasley YZ Patt 2002 Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 1206 1213 10.1053/jhep.2002.36780 10.1053/jhep.2002.36780 12395331 (Pubitemid 35253437)
36. JM Yuan S Govindarajan K Arakawa MC Yu 2004 Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US Cancer 101 1009 1017 10.1002/cncr.20427 10.1002/cncr.20427 15329910 (Pubitemid 39100435)
37. T Chiba Y Matsuzaki M Abei J Shoda N Tanaka T Osuga T Aikawa 1996 The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma Am J Gastroenterol 91 1195 1203 8651170